Cargando…
Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823520/ https://www.ncbi.nlm.nih.gov/pubmed/31674161 http://dx.doi.org/10.3346/jkms.2019.34.e287 |
_version_ | 1783464547893379072 |
---|---|
author | Lee, Young-Ji Lee, Ga-Won Seo, Wan-Seok Koo, Bon-Hoon Kim, Hye-Geum Cheon, Eun-Jin |
author_facet | Lee, Young-Ji Lee, Ga-Won Seo, Wan-Seok Koo, Bon-Hoon Kim, Hye-Geum Cheon, Eun-Jin |
author_sort | Lee, Young-Ji |
collection | PubMed |
description | BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofeedback augmentation group (n = 12) and the medication-only (treatment as usual [TAU]) group (n = 12). The neurofeedback augmentation group underwent combined therapy comprising medication and 12–24 sessions of neurofeedback training for 12 weeks. To assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, pre- and post-treatment blood samples were obtained. Patients were evaluated using the Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and at the 1-, 4-, and 12-week. RESULTS: From baseline to week 12, neurofeedback training reduced mean scores on HAM-D, BDI-II, CGI-S, and SDS, and increased mean EQ-5D-5L tariff score. In the neurofeedback augmentation group, the response and remission rates were 58.3% and 50.0%, respectively, at week 12. Changes in HAM-D, EQ-5D-5L tariff score, and SDS were significantly larger in the neurofeedback group than in the medication-only (TAU) group. No significant difference in BDNF level was found pre- vs. post-treatment in any of the groups. CONCLUSION: Despite the small sample size, these results suggest that neurofeedback treatment may be effective as an augmentation treatment, not only for depressive symptoms, but also for functional recovery, in patients with TRD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004183 ClinicalTrials.gov Identifier: NCT04078438 |
format | Online Article Text |
id | pubmed-6823520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-68235202019-11-06 Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study Lee, Young-Ji Lee, Ga-Won Seo, Wan-Seok Koo, Bon-Hoon Kim, Hye-Geum Cheon, Eun-Jin J Korean Med Sci Original Article BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofeedback augmentation group (n = 12) and the medication-only (treatment as usual [TAU]) group (n = 12). The neurofeedback augmentation group underwent combined therapy comprising medication and 12–24 sessions of neurofeedback training for 12 weeks. To assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, pre- and post-treatment blood samples were obtained. Patients were evaluated using the Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and at the 1-, 4-, and 12-week. RESULTS: From baseline to week 12, neurofeedback training reduced mean scores on HAM-D, BDI-II, CGI-S, and SDS, and increased mean EQ-5D-5L tariff score. In the neurofeedback augmentation group, the response and remission rates were 58.3% and 50.0%, respectively, at week 12. Changes in HAM-D, EQ-5D-5L tariff score, and SDS were significantly larger in the neurofeedback group than in the medication-only (TAU) group. No significant difference in BDNF level was found pre- vs. post-treatment in any of the groups. CONCLUSION: Despite the small sample size, these results suggest that neurofeedback treatment may be effective as an augmentation treatment, not only for depressive symptoms, but also for functional recovery, in patients with TRD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004183 ClinicalTrials.gov Identifier: NCT04078438 The Korean Academy of Medical Sciences 2019-10-24 /pmc/articles/PMC6823520/ /pubmed/31674161 http://dx.doi.org/10.3346/jkms.2019.34.e287 Text en © 2019 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Young-Ji Lee, Ga-Won Seo, Wan-Seok Koo, Bon-Hoon Kim, Hye-Geum Cheon, Eun-Jin Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title | Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title_full | Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title_fullStr | Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title_full_unstemmed | Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title_short | Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study |
title_sort | neurofeedback treatment on depressive symptoms and functional recovery in treatment-resistant patients with major depressive disorder: an open-label pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823520/ https://www.ncbi.nlm.nih.gov/pubmed/31674161 http://dx.doi.org/10.3346/jkms.2019.34.e287 |
work_keys_str_mv | AT leeyoungji neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy AT leegawon neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy AT seowanseok neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy AT koobonhoon neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy AT kimhyegeum neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy AT cheoneunjin neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy |